S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:SVRA

Savara (SVRA) Stock Forecast, Price & News

$3.74
-0.04 (-1.06%)
(As of 09/25/2023 ET)
Compare
Today's Range
$3.62
$3.78
50-Day Range
$3.14
$3.88
52-Week Range
$1.08
$4.21
Volume
485,291 shs
Average Volume
424,644 shs
Market Capitalization
$505.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Savara MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
33.7% Upside
$5.00 Price Target
Short Interest
Healthy
2.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.02 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

646th out of 962 stocks

Pharmaceutical Preparations Industry

289th out of 449 stocks


SVRA stock logo

About Savara (NASDAQ:SVRA) Stock

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

SVRA Price History

SVRA Stock News Headlines

Molgramostim: Savara's Single Shot At Success
Savara Inc.'s (NASDAQ:SVRA) Path To Profitability
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
10% Owner of Savara Makes $999K Buy
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Savara Recent Insider Activity
999K Reasons To Be Bullish On Savara Stock
Savara: A Speculative Play
Savara Prices Share Offering at $3 a Share
Savara joins Russell 3000
Savara (SVRA) Gets a Buy from H.C. Wainwright
See More Headlines
Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SVRA Company Calendar

Last Earnings
8/10/2023
Today
9/25/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SVRA
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+33.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-38,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$260,000.00
Book Value
$0.95 per share

Miscellaneous

Free Float
128,982,000
Market Cap
$505.54 million
Optionable
Optionable
Beta
0.89
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Robert N. Neville (Age 51)
    Chairman of the Board, Chief Executive Officer
  • Taneli Jouhikainen (Age 51)
    President, Chief Operating Officer
  • David L. Lowrance (Age 50)
    Chief Financial Officer
  • Nevan C. Elam (Age 49)
    Independent Director
  • Richard J. Hawkins (Age 68)
    Independent Director
  • Joseph S. McCracken Ph.D. (Age 64)
    Independent Director
  • Matthew Pauls J.D.Matthew Pauls J.D. (Age 46)
    Independent Director
  • Yuri Pikover (Age 56)
    Independent Director













SVRA Stock - Frequently Asked Questions

Should I buy or sell Savara stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SVRA shares.
View SVRA analyst ratings
or view top-rated stocks.

What is Savara's stock price forecast for 2023?

2 brokerages have issued 1 year price targets for Savara's stock. Their SVRA share price forecasts range from $4.00 to $6.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price.
View analysts price targets for SVRA
or view top-rated stocks among Wall Street analysts.

How have SVRA shares performed in 2023?

Savara's stock was trading at $1.55 at the beginning of 2023. Since then, SVRA stock has increased by 141.3% and is now trading at $3.74.
View the best growth stocks for 2023 here
.

When is Savara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SVRA earnings forecast
.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by many different retail and institutional investors. Top institutional investors include Caxton Corp (3.68%), BlackRock Inc. (4.29%), Jennison Associates LLC (2.34%), Geode Capital Management LLC (1.61%), State Street Corp (0.99%) and Northern Trust Corp (0.55%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken, Matthew Pauls, Raymond Dennis Pratt and Rick Yang.
View institutional ownership trends
.

How do I buy shares of Savara?

Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $3.74.

How much money does Savara make?

Savara (NASDAQ:SVRA) has a market capitalization of $505.54 million and generates $260,000.00 in revenue each year. The company earns $-38,150,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The official website for the company is www.savarapharma.com. The company can be reached via phone at 512-614-1848, via email at ir@savarapharma.com, or via fax at 858-552-0876.

This page (NASDAQ:SVRA) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -